Abstract
Epidermal growth factor receptor (EGFR) signalling has previously been identified as an important prognostic factor in patients with head and neck cancer (HNC). EGFR has been confirmed in a phase III randomized trial as a critical target in combination with radiation therapy for locally advanced HNC patients. Provocatively, the outcomes, at first glance, appear similar to patients treated with conventional chemo-radiation; but with less mucosal toxicity. Promising options for EGFR inhibition include targeting the epidermal growth factor receptor (EGFR) with tyrosine kinase inhibitors (EGFR-TKIs), and monoclonal antibodies to prevent ligand binding. There are limitations to EGFR inhibition as only 10% of patients respond to EGFR blockade with advanced disease; therefore, immunohistochemistry, fluorescence in situ hybridization (FISH), gene arrays and molecular analysis techniques have been performed in an effort to predict which patients will respond to EGFR targeted therapies. Are there new issues and discoveries regarding EGFR biology that will provide information to determine at the outset, which patients will respond to this type of therapy, and which patients will benefit from alternative “ targeted agents ” ? In development are agents that target selective parts of the EGFR pathway such as Akt, mTor or Src kinase inhibitors. Novel drugs attacking both the EGFR and angiogenic pathways may provide wider applicability and improve radiation response further. This review will update head and neck specialists as to relevant new information regarding EGFR inhibition, alternative approaches with targeted agents and challenges facing oncology investigators to better define the appropriate patient population to benefit from these new agents.
Keywords: EGFR, gefitinib, erlotinib, cetuximab, head and neck cancer and radiation
Current Cancer Therapy Reviews
Title: EGFR Inhibitors and Radiation in HNSCC
Volume: 3 Issue: 4
Author(s): Laura QM Chow, Changhu Chen and David Raben
Affiliation:
Keywords: EGFR, gefitinib, erlotinib, cetuximab, head and neck cancer and radiation
Abstract: Epidermal growth factor receptor (EGFR) signalling has previously been identified as an important prognostic factor in patients with head and neck cancer (HNC). EGFR has been confirmed in a phase III randomized trial as a critical target in combination with radiation therapy for locally advanced HNC patients. Provocatively, the outcomes, at first glance, appear similar to patients treated with conventional chemo-radiation; but with less mucosal toxicity. Promising options for EGFR inhibition include targeting the epidermal growth factor receptor (EGFR) with tyrosine kinase inhibitors (EGFR-TKIs), and monoclonal antibodies to prevent ligand binding. There are limitations to EGFR inhibition as only 10% of patients respond to EGFR blockade with advanced disease; therefore, immunohistochemistry, fluorescence in situ hybridization (FISH), gene arrays and molecular analysis techniques have been performed in an effort to predict which patients will respond to EGFR targeted therapies. Are there new issues and discoveries regarding EGFR biology that will provide information to determine at the outset, which patients will respond to this type of therapy, and which patients will benefit from alternative “ targeted agents ” ? In development are agents that target selective parts of the EGFR pathway such as Akt, mTor or Src kinase inhibitors. Novel drugs attacking both the EGFR and angiogenic pathways may provide wider applicability and improve radiation response further. This review will update head and neck specialists as to relevant new information regarding EGFR inhibition, alternative approaches with targeted agents and challenges facing oncology investigators to better define the appropriate patient population to benefit from these new agents.
Export Options
About this article
Cite this article as:
Chow QM Laura, Chen Changhu and Raben David, EGFR Inhibitors and Radiation in HNSCC, Current Cancer Therapy Reviews 2007; 3 (4) . https://dx.doi.org/10.2174/157339407782497004
DOI https://dx.doi.org/10.2174/157339407782497004 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preparation and <i>In vitro, Ex vivo</i> Evaluation of Benzidamine Hydrochloride
Loaded Fast Dissolving Oral Strip Formulations: Treatment of Oral
Mucositis Due to Side Effects of Chemotherapy and Radiotherapy
Letters in Drug Design & Discovery Anti-cancer Potential of <i>Hypericum</i> spp. with Focus on <i>Hypericum Perforatum</i>: A Review of the Literature
Current Traditional Medicine HIV-1 Rev Multimerization: Mechanism and Insights
Current HIV Research Induction of Tumour Cell Senescence: A New Strategy in Anticancer Treatment
Medicinal Chemistry Reviews - Online (Discontinued) Enzymes To Die For: Exploiting Nucleotide Metabolizing Enzymes for Cancer Gene Therapy
Current Gene Therapy Cubic Phases, Cubosomes and Ethosomes for Cutaneous Application
Current Pharmaceutical Design A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs
Drug Metabolism Letters Nitroimidazole Radiopharmaceuticals in Bioimaging: Part I: Synthesis and Imaging Applications
Current Radiopharmaceuticals HR-MAS NMR Spectroscopy: A Practical Guide for Natural Samples
Current Organic Chemistry Vitamin D Deficiency in Advanced Laryngeal Cancer and its Association with Pharyngocutaneous Fistula Following Total Laryngectomy
Current Drug Safety Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Radiology of Oropharyngeal Cancer - Institutional Experience and Literature Review -
Current Cancer Therapy Reviews Eating Green: Shining Light on the Use of Dietary Phytochemicals as a Modern Approach in the Prevention and Treatment of Head and Neck Cancers
Current Topics in Medicinal Chemistry Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Current Topics in Medicinal Chemistry Tyrosine Kinase Receptor Transactivation Associated to G Protein-Coupled Receptors
Current Drug Targets The Influence of Macrophages and the Tumor Microenvironment on Natural Killer Cells
Current Molecular Medicine Involvement of Metabolites and Non-coding RNAs in Diseases
Current Pharmaceutical Biotechnology PET Imaging for Gene & Cell Therapy
Current Gene Therapy